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Abstract 
Background: Previous gestational diabetes (pGDM) is a risk factor of type 2 diabetes, hypertension and cardiovascu-
lar diseases. Homocysteine is one of markers of cardiovascular risk. The aim of this study was to assess the homocyst-
eine levels in women with pGDM and to evaluate its relationship with current carbohydrate metabolism and nourish-
ment status.
Methods: The study group comprised 199 women at 7.8 ± 1.0 years after pGDM and 50 control women in whom 
pGDM was excluded. The analyzed parameters: BMI, WHR, body composition (Tanita SC-330S analyzer), glucose and 
insulin levels in oral glucose tolerance test (OGTT), insulin resistance index (HOMA-IR), HbA1c, lipid profile, homocyst-
eine, creatinine and creatinine clearance. The Mann–Whitney test and Chi–squared test were used for comparison 
of continuous and nominal variables, respectively. Correlations between continuous variables in each group were 
analyzed using Spearman’s rank correlation coefficient (Rs). A logarithmic transformation was applied for variables 
with non-normal distribution.
Results: There were no differences between the pGDM women and controls in terms of age, number of childbirths, 
time from indexed pregnancy, pre-pregnancy BMI, or current anthropometric parameters. In pGDM women HbA1c 
and all glucose levels in OGTT were significantly higher, but still within the normal range. No significant differences 
were found in homocysteine levels, HOMA-IR, blood lipids, creatinine and creatinine clearance. Homocysteine levels 
did not differ significantly in subgroups categorized according to the current OGTT results or BMI. Carbohydrate 
metabolism disorders, overweight and obesity were associated with higher creatinine clearance. Positive correla-
tion between homocysteine and creatinine (r = 0.21, p < 0.004), and a negative correlation with creatinine clearance 
(r = −0.16, p < 0.03) were found.
Conclusions: In women with pGDM, homocysteine is not a marker of glucose tolerance disturbances and cardio-
vascular risk. Increased glomerular filtration rate, observed in more severe disorders of carbohydrate metabolism and 
greater BMI, may temporarily protect against an increase of proatherogenic homocysteine.
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Background
A history of gestational diabetes (GDM) is associated 
with an increased risk of type 2 diabetes, hypertension 
and cardiovascular diseases [1–4]. Women with GDM 
are characterized by increased insulin resistance, which 
is a risk factor for atherosclerosis [5]. Early atheroscle-
rotic lesions in women with GDM are manifested by 
thickening of the intima media complex as revealed by 
ultrasound imaging [6]. The increased levels of proin-
flammatory cytokines observed in pregnancies com-
plicated by GDM indicate the presence of subclinical 
inflammation [7].
Homocysteine (Hcy) is one of the markers of increased 
risk of cardiovascular diseases [8]. The proatherogenic 
activity of Hcy results from its cytotoxic effect on endothe-
lial cells because it induces or promotes the formation of 
Open Access
*Correspondence:  pmoleda@wp.pl 
1 Department of Diabetology and Internal Medicine, Pomeranian Medical 
University in Szczecin, Siedlecka 2 Str, 72-010 Police, Poland
Full list of author information is available at the end of the article
Page 2 of 6Molęda et al. Diabetol Metab Syndr  (2015) 7:93 
atherosclerotic plaque [9]. Increased Hcy levels promote 
oxidative stress, have prothrombotic activity, affect the 
proliferation of vascular smooth muscle cells, and induce/
promote subclinical inflammation [10–12]. It has also 
been suggested that Hcy contributes to the development of 
insulin resistance associated with the metabolic syndrome, 
type 2 diabetes and atherogenesis [13–15].
There is a very limited number of studies on homocyst-
eine levels in women with GDM, but those existing report 
both normal and increased Hcy levels [6, 16–18]. Even less 
information can be found on Hcy in women with a his-
tory of GDM (pGDM), and these are single reports from 
studies on populations from Korea and Iran that indicated 
increased homocysteine levels in women several years 
after diagnosis of pGDM that correlated with an increased 
risk of developing type 2 diabetes [19, 20]. To date, no 
reports have been available on Hcy in women with pGDM 
in a European population. Moreover, no information is 
available on Hcy levels after a longer period of time from 
the diagnosis of GDM. The correlation between the levels 
of Hcy and carbohydrate disorders or nourishment status 
in women with pGDM have not been investigated.
Aim of the study
The aim of the study was to evaluate Hcy levels in women 
from a central-European population diagnosed with 
pGDM many years before and to compare these levels 




The study group comprised 199 women who had given 
birth to their children within the last 5–12  years and 
had been diagnosed with GDM based on an oral glu-
cose tolerance test (OGTT) conducted during pregnancy 
(pGDM group). The control group included 50 women 
of comparable age who had given birth during the same 
period of time and in whom GDM was excluded based 
on OGTT results during pregnancy (C group). The study 
had the approval of the Bioethics Committee of the 
Pomeranian Medical University, and written informed 
consent was obtained from all participants.
Methods
All study participants were interviewed to gather infor-
mation on the number and course of their pregnancies. 
The physical examination included an assessment of 
body mass with the calculation of body mass index [BMI 
(kg/m2)] and the measurement of waist and hip circum-
ference with the calculation of waist/hip ratio (WHR). 
Body composition was measured using a Tanita SC-330S 
analyzer (Tanita Corporation, Tokyo, Japan). An oral 
glucose tolerance test (OGTT, 75  g) was performed in 
all women. The OGTT analyzed the glucose level (enzy-
matic method, Cormay SA, Warsaw, Poland) and the 
insulin level (IRMA method, BioSource Europe SA, Niv-
elles, Belgium) at 0, 60 and 120 min of the test. Baseline 
glucose and insulin levels were used to calculate the insu-
lin resistance index (HOMA-IR) (the HOMA Calcula-
tor—Software v2.2.2) [21]. Glycated hemoglobin (HbA1c) 
was measured using the HPLC technique (Bio-Rad Labo-
ratories, Munich, Germany). Homocysteine levels were 
measured with the ELISA technique (Bio-Rad Laborato-
ries, Munich, Germany), and creatinine levels were meas-
ured using the kinetic alkaline picrate method (Integra 
kit, Roche, Rotkreuz, Switzerland). Creatinine clearance 
was calculated based on the Cocroft-Gault equation. The 
study included only women with normal plasma creati-
nine levels (<106 µmol/L).
Statistical analysis
STATISTICA version 7.1 software (StatSoft Inc., Tulsa, 
OK, USA) was used for database management and statis-
tical analysis. The Mann–Whitney test and Chi-squared 
test were used for comparison of continuous and nominal 
variables, respectively. Correlations between continuous 
variables in each group were analyzed using Spearman’s 
rank correlation coefficient (Rs). Multiple linear regres-
sion model was used for multivariate analysis adjusted 
for age. A logarithmic transformation was applied for 
variables with non-normal distribution. A value of <0.05 
was considered to be statistically significant. Our study 
had 80  % statistical power to detect true differences in 
mean Hcy concentration between the study and control 
group equal to 1.6 µmol/L.
Results
Both groups were tested after approx. 7.8  years of an 
indexed pregnancy, were of comparable age, had a simi-
lar number of pregnancies and births, and had similar 
anthropometric characteristics and body compositions 
(Table 1). They also had similar degrees of insulin resist-
ance as reflected by HOMA-IR, lipids and creatinine lev-
els. In women with pGDM, the mean levels of HbA1c, 
fasting glucose, and glucose between 60 and 120  min 
after the OGTT were significantly greater than in the 
controls, but still within the normal range. No difference 
in the Hcy levels in either group was found (Table 1).
Based on the result of the current OGTT and in accord-
ance with the WHO guidelines [22], the study population 
was divided into 4 subgroups: normal glucose tolerance 
(NGT), impaired fasting glucose (IFG), impaired glucose 
tolerance (IGT), and diabetes mellitus (DM).
Disorders of carbohydrate metabolism based on the 
results of the OGTT were more frequent in the pGDM 
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group (43.2 vs 12.0  %, ξ2  =  18.7, p  <  0.001) (Table  2). 
Another analysis was based on the current BMI of 
women categorized as normal body mass (NW), over-
weight (OW) and obese (OB). In both the study and con-
trol groups the percentage of women with normal body 
mass and those that were overweight and obese was com-
parable (ξ2 = 0.18; NS) (Table 2).
Homocysteine levels in the pGDM group were esti-
mated in subgroups of different carbohydrate metabo-
lism disorders (IFG, IGT, DM) and were comparable 
and did not differ from the values found in women with 
NGT (Table  3). The analysis of the NTG-pGDM 
(n = 113) and NTG-C (n = 44) subgroups also revealed 
no differences in the homocysteine levels (7.7 ± 2.5 and 
7.6 ±  3.6  µmol/L; respectively, NS). There were signifi-
cant differences in terms of age, BMI, HOMA-IR, HbA1c, 
HDL-cholesterol, triglycerides and creatinine clear-
ance levels between women with carbohydrate metabo-
lism disorders and those with normal glucose tolerance 
(Table 3).
There were no statistically significant differences in the 
homocysteine levels in different BMI subgroups. Women 
with a greater BMI were significantly older and had 
higher values of HOMA-IR, LDL-cholesterol, triglycer-
ides and creatinine clearance but had lower HDL-choles-
terol (Table 4).
No statistically significant correlation was found 
between homocysteine levels and body mass, BMI, 
WHR, content of body fat or non-adipose tissue. More-
over, no correlation was found between the homocyst-
eine levels and the metabolic parameters of glucose and 
insulin levels during the OGTT, HbA1c, HOMA IR 
index, and parameters of lipid metabolism. A positive 
correlation was found between Hcy and creatinine lev-
els (r =  0.21, p  <  0.004) and a negative correlation was 
found between Hcy and creatinine clearance (r = −0.16, 
p < 0.03). The multi-factor analysis of variance adjusted 
for age revealed that higher Hcy levels were associated 
only with higher plasma creatinine levels (β = 0.25, 95 % 
CI 0.11–0.39, p < 0.001).
Table 1 Characteristics of studied groups
BMI body mass index, C control group, HbA1c glycated hemoglobin, HOMA-IR homoeostasis model assessment insulin resistance, pGDM women with previous 
gestational diabetes, WHR waist/hip ratio
Parameter C (mean ± SD, n = 50) pGDM (mean ± SD, n = 199) p
Age (years) 36.8 ± 5.6 38.4 ± 6.6 NS
Number of pregnancies 1.9 ± 2.1 2.4 ± 1.4 NS
Number of deliveries 1.8 ± 2.4 2.1 ± 1.2 NS
Time since pGDM/pregnancy (years) 7.8±1.0 7.4 ± 0.7 NS
Body weight before pregnancy (kg) 61.6 ± 11.1 63.3 ± 13.1 NS
Body weight (kg) 68.7 ± 14.9 67.9 ± 15.2 NS
BMI before pregnancy (kg/m2) 21.9 ± 3.9 22.5 ± 4.1 NS
BMI (kg/m2) 25.4 ± 5.0 25.5 ± 5.6 NS
WHR 0.84 ± 0.07 0.86 ± 0.09 NS
Adipose tissue mass (kg) 22.6 ± 11.1 21.9 ± 10.2 NS
Lean body mass (kg) 46.1 ± 4.8 45.5 ± 6.1 NS
HbA1c (%) 5.4 ± 0.4 5.6 ± 0.4 <0.01
Glucose 0’ (mmol/L) 4.9 ± 0.6 5.3 ± 0.7 <0.0001
Glucose 60’ (mmol/L) 5.8 ± 1.9 8.3 ± 2.6 <0.0001
Glucose 120’ (mmol/L) 4.8 ± 1.1 6.4 ± 2.2 <0.0001
Insulin 0’ (µIU/mL) 13.7 ± 8.5 13.7 ± 8.7 NS
Insulin 60’ (µIU/mL) 83.8 ± 41.1 106.8 ± 62.6 <0.03
Insulin 120’ (µIU/mL) 47.5 ± 30.6 74.6 ± 58.7 <0.002
HOMA-IR 1.73 ± 1.03 1.76 ± 1.05 NS
Homocysteine (µmol/L) 7.56 ± 3.55 7.63 ± 2.66 NS
Total cholesterol (mmol/L) 4.99 ± 0.88 4.93 ± 1.0 NS
HDL-cholesterol (mmol/L) 1.71 ± 0.47 1.78 ± 0.47 NS
LDL-cholesterol (mmol/L) 2.79 ± 0.8 2.68 ± 0.93 NS
Triglycerides (mmol/L) 1.06 ± 0.97 1.11 ± 0.69 NS
Creatinine (µmol/L) 56.6 ± 9.7 58.3 ± 9.7 NS
Creatinine clearance (mL/min) 132.5 ± 33.2 126.3 ± 32.0 NS
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Discussion
A history of GDM is associated with an increased risk of 
type 2 diabetes. In the 10 years after the end of a preg-
nancy complicated by GDM, 20–70  % of women may 
have diabetes mellitus [1, 4, 23]. Our study was car-
ried out approximately 8  years following the diagnosis 
of pGDM revealed carbohydrate metabolism disorders 
in approximately 43 % of the subjects, but only 6.5 % of 
the women had diabetes. It can be assumed that the low 
prevalence of diabetes in the pGDM group could result 
from the fact that the majority of women (57  %) had 
normal body mass, whereas 24  % were overweight and 
approximately 19 % were obese.
It is not clear whether the increased risk of athero-
sclerosis and cardiovascular complications in women 
with pGDM results from carbohydrate metabolism dis-
orders developing or worsening over time, or whether 
it is related to other metabolic disorders. Hcy, which 
has proatherogenic activity, may be one such risk fac-
tor. The relationship between homocysteine levels and 
insulin resistance and the components of the metabolic 
syndrome has been demonstrated in a study on a general 
population [13]. In a prospective study of 170 Korean 
women with pGDM who were evaluated 4  years fol-
lowing childbirth, 10.8  % were diagnosed with diabetes 
mellitus and independent risk factors for developing dia-
betes and displayed elevated Hcy and elevated fasting 
glucose measured soon after delivery [19]. A study car-
ried out in Iran in women with pGDM evaluated 4 years 
following childbirth revealed significantly higher levels 
of Hcy compared with the control group [20]. Homo-
cysteine levels were higher in women with impaired 
glucose tolerance. However, the findings from studies 
assessing the relationship between homocysteine levels 
and carbohydrate metabolism disorders are inconsistent. 
Nevertheless, most of them do not confirm any correla-
tion [24–26].
Our study did not reveal any significant relationship 
between homocysteine levels and the severity of carbo-
hydrate metabolism disorders, components of the meta-
bolic syndrome, or current composition of body mass 
in women with a history of GDM. However, Hcy levels 
were positively correlated with plasma creatinine levels 
Table 2 The frequency of  glucose metabolism and  nutri-
tion disorders in studied groups
BMI body mass index, C control group, DM diabetes mellitus, IFG impaired 
fasting glucose, IGT impaired glucose tolerance, NGT normal glucose tolerance, 
NW normal body mass, OB obesity, OGTT oral glucose tolerance test, OW 
overweight, pGDM women with previous gestational diabetes
C (n = 50) pGDM (n = 199) p
OGTT result
 NGT n (%) 44 (88.0 %) 113 (56.8 %) ξ2 = 18.7, p < 0.001
 IFG n (%) 5 (10.0 %) 40 (20.1 %)
 IGT n (%) 1 (2.0 %) 33 (16.6 %)
 DM n (%) 0 (0.0 %) 13 (6.5 %)
BMI
 NW n (%) 27 (54.0 %) 114 (57.3 %) ξ2 = 0.18, NS
 OW n (%) 14 (28.0 %) 48 (24.1 %)
 OB n (%) 9 (18.0 %) 37 (18.6 %)
Table 3 Homocysteine and lipids’ levels in subgroups categorized according to the current OGTT results in pGDM group
BMI body mass index, C control group, DM diabetes mellitus, HbA1c glycated hemoglobin, HOMA-IR homoeostasis model assessment insulin resistance, IFG impaired 
fasting glucose, IGT impaired glucose tolerance, NGT normal glucose tolerance, OGTT oral glucose tolerance test, pGDM women with previous gestational diabetes
* p < 0.05 vs NGT, ** p < 0.01 vs NGT
+p < 0.05 vs IFG, ++ p < 0.01 vs IFG
^p < 0.05 vs NGT (adjusted for age), ^^ p < 0.01 vs NGT (adjusted for age)
#p < 0.05 vs IFG (adjusted for age), ## p < 0.01 vs IFG (adjusted for age)








Age (years) 37.4 ± 6.5 39.9 ± 6.2* 39.9 ± 6.4* 38.7 ± 8.3
BMI (kg/m2) 23.9 ± 4.3 26.6 ± 6.2*,^ 28.1 ± 6.4**,^^ 29.6 ± 6.8**,^^
HOMA-IR 1.51 ± 0.88 1.70 ± 0.86*,^ 2.24 ± 1.31**,^^ 2.62 ± 1.38**,^^
HbA1c (%) 5.53 ± 0.34 5.70 ± 0.39*,^ 5.76 ± 0.38**,^^ 6.19 ± 0.76**,^^
Homocysteine (µmol/L) 7.73 ± 2.53 7.84 ± 3.02 7.24 ± 2.92 7.09 ± 1.88
Total cholesterol (mmol/L) 4.98 ± 1.08 5.03 ± 0.99 5.14 ± 1.03 5.16 ± 0.99
HDL-cholesterol (mmol/L) 1.93 ± 0.47 1.79 ± 0.46 1.59 ± 0.49**,^^ 1.43 ± 0.28**,++,^^,#
LDL-cholesterol (mmol/L) 2.64 ± 1.0 2.74 ± 0.93 2.80 ± 0.78 3.03 ± 0.80
Triglycerides (mmol/L) 0.89 ± 0.39 0.92 ± 0.40 1.61 ± 1.14**,+,^^,## 1.51 ± 0.74**,+,^^
Creatinine (mmol/L) 57.46 ± 9.72 58.34 ± 9.72 58.34 ± 7.96 57.46 ± 7.07
Creatinine clearance (mL/
min)
120.8 ± 28.7 127.7 ± 32.9 134.9 ± 32.5*,^^ 150.4 ± 43.7*,^
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and negatively correlated with creatinine clearance lev-
els. Another study of subjects at risk for diabetes (fam-
ily history of DM, overweight or women with pGDM) 
demonstrated a similar finding [27]. It is known that 
renal function affects the blood Hcy level [28]. How-
ever, it was still surprising that the correlation between 
Hcy levels and glomerular filtration rate observed in our 
study was so strong in young women without comor-
bidities and creatinine levels within the normal range. 
Significantly higher values of creatinine clearance were 
found in women with more severe carbohydrate metab-
olism disorders and in overweight and obese women. 
The increased glomerular filtration rate (GFR) observed 
in these groups resulted from greater body mass and 
perhaps higher glucose levels [29]. The increased GFR 
observed in these groups may exert a protective effect 
and prevent the increase in homocysteine levels in the 
blood. Slowly decreasing GFR with age may lead to an 
increase in Hcy levels, with subsequent adverse effects on 
the micro- and macrocirculation in patients with type 2 
diabetes [26, 30–32].
The strong points of our study include the large homo-
geneous population of women with a history of GDM, 
a precisely selected control group and a wide panel of 
anthropometric and metabolic tests. The study also has 
some limitations. It did not consider factors affecting Hcy 
levels such as levels of vitamin B6, B12, and folic acid, the 
use of stimulants or diet. Nevertheless, all of the analyzed 
women had no comorbidities and followed a typical cen-
tral European diet; these additional parameters were not 
considered in other, similar studies.
Conclusions
The study revealed that in women with a history of 
gestational diabetes, homocysteine is not a marker of 
increased cardiovascular risk, as its levels are not corre-
lated with current carbohydrate metabolism disorders, 
overweight status or obesity. Increased GFR was related 
to more severe disorders of carbohydrate metabolism and 
greater body mass being risk factors for cardiovascular 
diseases, it may temporarily protect against an increase 
in the level of proatherogenic homocysteine.
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